Skip to content

Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch

Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch as a Primary Bariatric Procedure. 5 Year Patient Follow

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02692469
Acronym
DSvsSADI
Enrollment
140
Registered
2016-02-26
Start date
2016-04-30
Completion date
2026-04-30
Last updated
2016-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Bariatric Surgery, Obesity, Laparoscopy

Brief summary

Will a laparoscopic Single-Anastomosis Duodenal-ileal Bypass with Sleeve Gastrectomy produce similar or superior results when compared to a laparoscopic Duodenal Switch, as a primary surgical procedure for weight loss in bariatric patients over a 5 year period?

Detailed description

The aims of this study are: (a) to compare SADI vs DS as a primary bariatric procedure for weight loss; (b) to compare the minor and major complications of SADI vs DS (c) to compare SADI vs DS for remission rates of type 2 diabetes (d) to compare SADI vs DS for remission rates of hypertension (e) to compare SADI vs DS for weight regain at 5 years (f) to compare SADI vs DS for metabolic alterations. The investigators hypothesize that both procedures will have similar weight loss and metabolic remission results. If the complication rates of SADI are similar or superior to the complication rates of the DS, then the investigators could propose the SADI as a viable alternative to the DS in patients with high BMIs requiring increased weight loss. The investigators will conduct a prospective randomized study. The study will include 140 patients who are scheduled for bariatric procedures. The patients will be stratified into 2 groups. The first group will continue according to the standard bariatric preoperative protocol and will be assigned to a DS. The second group will also follow standard bariatric preoperative protocol but will be assigned to a SADI. Follow up of all patients will continue according to the usual bariatric clinic guidelines. From literature, the mean excess body weight loss is 77.65% with standard deviation of 21% for Duodenal Switch bariatric surgery. If there is in truth no difference between the Duodenal Switch and SADI for excess body weight loss, then 140 patients (70 per group) are required to have 80% power for the lower limit of a one-sided 97.5% confidence interval (or equivalently a 95% two-sided confidence interval) will be above the non-inferiority limit of -10%. Participants must meet ALL of the following inclusion criteria: * Fulfilled criteria for bariatric surgery as coined by National Institutes of Health. * Their age is ≥18 years and ≤70 years * Able and willing to give written consent Participants who meet any of the following criteria at the time of the baseline visit are NOT eligible to be enrolled in this study: * Contra-indication to general anesthesia * Any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure * Pregnant or lactating female (Women of child bearing potential must take a pregnancy test prior to surgery) * History of alcohol abuse (\>30 g/day in men or \>20 g/day in women)

Interventions

Bariatric procedure

PROCEDUREDuodenal-ileal Bypass with Sleeve Gastrectomy

Bariatric procedure

Sponsors

McMaster University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Participants must meet ALL of the following inclusion criteria: * Fulfilled criteria for bariatric surgery as coined by National Institutes of Health. * Their age is ≥18 years and ≤70 years * Able and willing to give written consent

Exclusion criteria

* Participants who meet any of the following criteria at the time of the baseline visit are NOT eligible to be enrolled in this study: * Contra-indication to general anesthesia * Any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure * Pregnant or lactating female (Women of child bearing potential must take a pregnancy test prior to surgery) * History of alcohol abuse (\>30 g/day in men or \>20 g/day in women)

Design outcomes

Primary

MeasureTime frameDescription
Excess weight loss5 yearsBMI and body weight will be measured and compared to preoperative reference values

Secondary

MeasureTime frameDescription
Remission of type 2 diabetes5 yearsThe presence and remission of type 2 diabetes will be diagnosed according to the American Diabetes Association's current criteria: 1. A1C ≥6.5 percent, OR 2. FPG ≥126 mg/dL (7.0 mmol/L), OR 3. Two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an OGTT, OR 4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).
Remission of hypertension5 yearsThe presence and remission of hypertension will be diagnosed by the definitions suggested in 2003 by the seventh report of the Joint National Committee (JNC 7) and are based upon the average of two or more properly measured readings at each of two or more office visits after an initial screen: * Normal blood pressure: systolic \<120 mmHg and diastolic \<80 mmHg * Prehypertension: systolic 120 to 139 mmHg or diastolic 80 to 89 mmHg (see Prehypertension) * Hypertension: * Stage 1: systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg * Stage 2: systolic ≥160 mmHg or diastolic ≥100 mmHg
Surgical complications1 yearAccording to the Clavien-Dindo Classification of surgical complications
Metabolic alterations5 yearsBlood levels will be measured pre-operatively a on a regular schedule after surgery for: zinc, magnesium, phosphate, albumin, PTH, HbA1C, ferritin, calcium, Iron binding capacity, total proteins, Hb, Cholesterol levels, LDL, Vit. D, Vit. A and Vit. B12 to ensure they are in normal range.

Contacts

Primary ContactDennis Hong, MD FRCSC
dennishong70@gmail.com905 522-1155

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026